Axcellant have a rich history of supporting the development of many agents that are currently being used in routine clinical practice to extend the life or cure patients with a range of solid tumours and haematological malignancies.
Whether it is the various generations of monoclonal antibody epidermal growth factor receptor (EGFR) inhibitors; small molecule tyrosine kinase inhibitors; poly ADP ribose polymerase (PARP) inhibitors; antiandrogens and the various immunotherapies we have been very much at the heart of their development and continue to be involved in the subsequent generations of these important products.
The highly specialised skills of our regulatory and clinical operations team have also given us the opportunity to be involved with advanced therapies such as chimeric antigen receptor T-cell (CAR-T) therapies and gene transfer.
We have successfully executed many programmes targeting niche cohorts and involving a broad multidisciplinary teams at hospitals (e.g.: radioembolisation. contrast for cardiological imaging).